As part of our research programme, we have synthesized the title compound as an intermediate for the preparation of a zwitterionic analogue of the atypical antipsychotic, clozapine. The starting material, desmethylclozaine, 1 was synthesized in accordance with a previously reported literature procedure [1] . Subsequent treatment of 1 with benzyl 2-bromoacetate (2) afforded the title compound 3 in very good yield.
To a solution of desmethylclozapine (1, 503 mg, 1.61 mmol) and anhydrous triethylamine (0.451 mL, 3.23 mmol) in anhydrous 1,2-dimethoxyethane (25 mL) was added benzyl 2-bromoacetate (2, 0.287 mL, 1.81 mmol) via syringe. The reaction mixture was stirred at room temperature for 3 hours, filtered and then evaporated to dryness. The residue was treated with distilled water (10 mL) and extracted with dichloromethane (4 ´ 50 mL). The combined organic fractions were dried with anhydrous sodium sulfate, filtered, then evaporated to dryness. The resulting residue was purified using flash chromatography (silica gel 230-400 mesh, ethyl acetate:hexane, 1:1). The fractions containing product were combined and evaporated to dryness affording a yellow oil that solidified on standing. Recrystallisation from dichloromethane-hexane gave the title compound 3 as bright yellow prisms (536 mg, 72%). 
UV ((EtOH
; λ max nm; log 10 e): 209 (4.55), 228 (4.43), 260 (4.28), 297 (4.09).
